Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bone remodelling relies on tightly controlled cycles of bone resorption and formation, mediated by osteoclasts and osteoblasts, respectively. The past two decades have seen a huge increase in our understanding of immune modulation and disruption of bone homeostasis in rheumatic diseases; identification of the molecular pathways responsible for accelerated bone loss in such conditions has given rise to potential novel therapeutic targets. Most recently, the role of microRNAs in inflammatory and noninflammatory bone loss raises the intriguing possibility that modification of cellular protein translation could also be a treatment strategy for bone damage.

Original publication

DOI

10.1016/j.drudis.2014.06.025

Type

Journal article

Journal

Drug Discov Today

Publication Date

08/2014

Volume

19

Pages

1178 - 1185

Keywords

Animals, Arthritis, Bone Remodeling, Bone and Bones, Humans, Inflammation, Osteoblasts, Osteoclasts